SCHEMBL2366947

SCHEMBL2366947

NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)Cc1cccs1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.56
TNIK Q9UKE5 1/20 0.56
PIP5K1C O60331 1/20 0.55
LMNA P02545 5/20 0.53
POLB P06746 4/20 0.53
TP53 P04637 2/20 0.53
MAPK8 P45983 2/20 0.53
NPC1 O15118 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
HSD17B10 Q99714 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
CHEK1 O14757 1/20 0.52
AURKA O14965 1/20 0.52
DAPK3 O43293 1/20 0.52
PRKD3 O94806 1/20 0.52
NTRK1 P04629 1/20 0.52
FYN P06241 1/20 0.52
RET P07949 1/20 0.52
MET P08581 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16699821 0.88 TNIK (0.63) TNIK
SCHEMBL2367246 0.79 TNIK (0.65) MAPTTNIKPIP5K1CLMNAPOLB
SCHEMBL13224732 0.77 TNIK (0.84) MAPTTNIKPIP5K1CLMNAPOLB
SCHEMBL3394448 0.77 SMN1; SMN2 (0.58) MAPTLMNAPOLBTP53MAPK8
SCHEMBL16699829 0.76 TNIK (0.68) TNIK
SCHEMBL2367283 0.76 PIP5K1C (0.69) MAPTTNIKPIP5K1CLMNAPOLB
SCHEMBL6651050 0.76 MEN1 (0.74) MAPTPOLBNPC1SMN1; SMN2HSD17B10
Ammonia Solution, Strong SCHEMBL29042444 0.74 MEN1 (0.72) MAPTPOLBNPC1SMN1; SMN2HSD17B10
SCHEMBL16700839 0.74 TNIK (0.64) TNIK
SCHEMBL3394594 0.72 TNIK (0.79) MAPTTNIKPIP5K1CLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364149-B1 TNIK INHIBITOR AND THE USE NAT CANCER CT (JP) 2014-05-07 EP disclosed
CN-102227218-B Tnik inhibitor and use thereof CARNA BIOSCIENCES INC 2014-04-02 CN disclosed
CN-102227218-A Tnik inhibitor and use thereof TESSHI YAMADA 2011-10-26 CN disclosed
EP-2364149-A1 TNIK INHIBITOR AND THE USE National Cancer Center (JP) 2011-09-14 EP disclosed
US-20100216795-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI 2010-08-26 US disclosed
WO-2010064111-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI (JP) 2010-06-10 WO disclosed
US-20100137386-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216795-A1 TNIK INHIBITOR AND THE USE TNIK, TNNI3K, TNK1 MAPT 3204/4885TNIK 1/4885PIP5K1C 352/4885
US-20100137386-A1 TNIK INHIBITOR AND THE USE TNIK, TNNI3K, TNK1 MAPT 2295/4885TNIK 1/4885PIP5K1C 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.